--New assays for the Panther Fusion and Novodiag Systems further build on Hologic’s leading molecular scalable solutions offering to European customers-- The Panther Fusion SARS-CoV-2/Flu A/B/RSV ...
MARLBOROUGH, Mass.--(BUSINESS WIRE)--Hologic, Inc. (Nasdaq: HOLX) announced it has received CE marking for two new molecular assays, Panther Fusion EBV Quant Assay and Panther Fusion BKV Quant Assay, ...
Hologic’s HOLX fully automated, high-throughput Panther platform remains the foundation of its molecular diagnostics business. The Panther Fusion module, a 2016 addition to the base system, provides ...
Hologic’s fiscal first quarter outpaced our expectations, despite the ongoing headwind of declining COVID-19 diagnostics. The impressive underlying growth in nonpandemic diagnostics should play a ...
MARLBOROUGH, Mass.--(BUSINESS WIRE)--Hologic, Inc. (Nasdaq: HOLX) announced today that it has been awarded a $19 million contract from the Biomedical Advanced Research and Development Authority (BARDA ...
After seeing diagnostics revenues increase by 450% last quarter to meet global COVID-19 demands, Hologic continues to reinvest the proceeds into its testing divisions, now with its third ...
Hologic is acquiring molecular diagnostic assay developer Diagenode for $159 million, and more M&A could be around the corner. Belgium-based Diagenode provides more than 30 real-time polymerase chain ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results